Soligenix Closes Patient Enrollment In orBec Phase 2 Trial
The Phase 2 trial enrolled 140 patients who have been randomised to either orBec or placebo at a 2:1 ratio. The primary endpoint of this trial is the
BeOne Medicines is set to invest $300m in expanding its manufacturing and research operations at the Princeton West Innovation Campus in Hopewell, New Jersey, US.